Locally advanced cervical cancer remains an area of high therapeutic need, with recent trials failing to demonstrate evidence of benefit from adjuvant chemotherapy or immune checkpoint blockade administered concurrent with ...
Mar 27, 2023
0
8
New data from a Yale Cancer Center-led clinical trial shows improved rates of survival and reduced risk of recurrence in patients taking osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC). NSCLC is the ...
Jan 31, 2023
0
21
Today, the University of Colorado Cancer Center released new research that showcases chemotherapy treatment before and after surgery for pancreatic cancer as the most effective combination for patients.
Dec 8, 2022
0
171
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...
Aug 9, 2022
0
20
In a new large national study led by researchers at the American Cancer Society (ACS), Black patients diagnosed with early-onset colorectal cancer received worse and less timely care than their white counterparts. Differences ...
May 31, 2022
0
1
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumor resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute ...
Oct 1, 2021
0
5
The Phase III IMpower010 trial evaluating atezolizumab vs. best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients ...
Sep 9, 2021
0
0
(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant ...
Jul 9, 2021
0
2
Obese patients with colorectal cancer receive lower cumulative doses of adjuvant chemotherapy, relative to their body surface area (BSA), than non-obese patients, show results from a large meta-analysis reported at the ESMO ...
Jul 2, 2021
0
2
(HealthDay)—For patients with early breast cancer, five years of zoledronate treatment after chemotherapy does not improve prognosis versus two years of treatment, according to a study published online June 24 in JAMA Oncology.
Jun 25, 2021
0
2
